Drugs / Al18F-NOTA-Pentixafor
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06773663 | Dec 2023 → May 2026 overdue | aldosterone-producing adrenal cortex adenoma | Peking Union Medical College Hospital | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Al18F-NOTA-Pentixafor | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06773663 ↗ |
| Modality | Diagnostic / imaging agent | “Al18F-NOTA-Pentixafor is an imaging agent targeting CXCR4” NCT06773663 ↗ |
| Route | Intravenous | “Participants will receive an intravenous injection of Al18F-NOTA-Pentixafor” NCT06773663 ↗ |
| Target | CXCR4 | “Al18F-NOTA-Pentixafor is an imaging agent targeting CXCR4” NCT06773663 ↗ |